Clinical trials
for patients

This study aims to confirm the effectiveness of SGLT2i medication for their disease.

The main objective is to determine whether the combination of patritumab deruxtecan and pembrolizumab administered before or after chemotherapy is more effective and safer compared to the standard combination of pembrolizumab and chemotherapy followed by surgery and adjuvant treatment with pembrolizumab, in order to improve the disease-free survival rate and other clinical indicators in patients with triple-negative breast cancer.

The primary objective is to characterize the safety, tolerability and dose-toxicity curve of zongertinib in combination with T-DXd or in combination with T-DM1 in patients with HER2 metastatic breast cancer (mBC) or metastatic gastric or gastroesophageal adenocarcinoma (mGEAC) by evaluating escalating dose levels with overdose monitoring to achieve the primary objective of determining maximum tolerated doses (MTDs) and/or doses for future development.

The purpose of this trial is to test whether the experimental drug RO7790121 is safe and effective for moderate to severe atopic dermatitis and to find out what effects, good or bad, RO7790121 has versus placebo in atopic dermatitis

The objective of this study is to evaluate a new drug (TUB-040) in two phases for patients with ovarian cancer or non-small cell lung cancer.